百时美施贵宝(BMY)
搜索文档
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Investopedia· 2024-09-27 22:18
Key TakeawaysBristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The pharmaceutical firm called Cobenfy the first new treatment for the illness in decades.Bristol Myers Squibb said Cobenfy gives patients an important new option to current schizophrenia therapy. Shares of Bristol Myers Squibb (BMY) rose Friday, a day after the Food and Drug Administration (FDA) approved the use of what the pharmaceutical firm called the first treatment for schizophrenia ...
Bristol Myers Squibb shares move higher on FDA approval of schizophrenia drug
Proactiveinvestors NA· 2024-09-27 21:41
About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
Benzinga· 2024-09-27 19:56
On Thursday, the FDA approved Bristol Myers Squibb & Co’s BMY Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults.Bristol-Myers added the treatment via Karuna Therapeutics deal for $330 per share in cash for a total equity value of $14 billion.Cobenfy represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selectively targeting M1 and M4 receptors in the brain without blocking D2 rece ...
Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress
Seeking Alpha· 2024-09-27 19:37
Taking into account the most recent developments, particularly the KarXT ( Cobenfy ) FDA approval , which is poised to be a game changer in the treatment of Schizophrenia, together with the significant advances in the oncology portfolioOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising m ...
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
Forbes· 2024-09-27 17:27
29 August 2024, Bavaria, Munich: The logo of the pharmaceutical company Bristol-Myers Squibb, (BMS) ... [+] is seen on the facade of the company's Munich headquarters on August 29, 2024 in Munich (Bavaria). The global biopharmaceutical company is engaged in the research, development and readiness of innovative medicines for patients with serious diseases. Photo: Matthias Balk/dpa (Photo by Matthias Balk/picture alliance via Getty Images)dpa/picture alliance via Getty ImagesBristol Myers Squibb stock (NYSE: ...
FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades
CNBC· 2024-09-27 06:46
The Food and Drug Administration on Thursday approved Bristol Myers Squibb's highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades. Schizophrenia affects how a person thinks, feels and behaves, and can cause paranoia, delusions, hallucinations, and changes in emotions, movements and behavior. Those symptoms can disrupt a patient's everyday life, making it difficult to go to school or work, socialize and compl ...
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
The Motley Fool· 2024-09-14 20:45
文章核心观点 - 医药行业是一个可靠的长期投资机会,因为药品需求将一直存在,直到疾病被根治[1] - 要成为行业领导者,公司需要擅长创新和开发更好的疗法[2] 布里斯托尔-迈尔斯-斯奎布公司 - 公司拥有10款销售额超过10亿美元的药品[2] - 公司的主打药品Revlimid正面临专利到期,但公司的新药正在逐步增长[2][3] - 公司有多个管线项目,历史上创新能力强,股息收益率也较高[3][4] 吉利德科学公司 - 公司是HIV药物市场的领导者,其主打药品Biktarvy市场份额持续增长[5] - 公司正在加强其肿瘤业务,肿瘤管线占公司总管线的一半以上[6] - 公司正在减少对HIV业务的依赖,股息增长也较好[6][7]
Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?
ZACKS· 2024-09-12 02:40
文章核心观点 - 公司近期股价有所上涨,主要得益于公司二季度业绩超预期,以及新药物的良好表现[1][3] - 公司正在通过战略性收购来应对主要药品面临的专利到期和竞争压力[4] - 公司正在实施成本削减计划,预计到2025年底可节省约15亿美元[7] - 公司债务水平较高,这是一大隐忧[8] 新药物推动公司增长 - 公司新药物如Opdualag、Reblozyl和Breyanzi表现良好,帮助公司抵御了主要老药品销售放缓的影响[3] - 其中,治疗地中海贫血的Reblozyl和治疗肿瘤的Opdualag销售表现尤为出色[3] - 公司正在努力拓展Opdualag的适应症,这将为公司带来进一步的收入增长[3] 主要老药品面临挑战 - 公司主要药品Revlimid(多发性骨髓瘤治疗)面临专利到期和仿制药竞争,对公司收入造成不利影响[5] - 公司另一主要药品Eliquis(抗凝血药)和Opdivo(免疫肿瘤药)也将在未来面临专利到期和销售放缓的风险[6] - 这三款药品合计占公司上半年总收入的61%,公司需要设法维持收入增长[6] 公司估值和财务状况 - 公司股价目前处于52周低位,估值水平较低,低于行业平均水平[9] - 公司二季度业绩超预期,带动了2024年全年盈利预测的上调[10][11] - 但公司债务水平较高,这可能会对未来发展造成一定压力[8]
Bristol Myers Squibb Dividend Yield Pushes Past 5%
Forbes· 2024-09-10 03:51
Forbes Community GuidelinesOur community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space.In order to do so, please follow the posting rules in our site's Terms of Service. We've summarized some of those key rules below. Simply put, keep it civil.Your post will be rejected if we notice that it seems to contain:False or intentionally out-of-context or misleading informationSpamInsults, profanity, incoh ...
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
The Motley Fool· 2024-09-08 16:56
文章核心观点 - 尽管市场表现不佳,但过去20个月对大多数投资者来说是非凡的时期,标准普尔500指数自2022年底以来已飙升40.9% [1] - 在这种不确定的时期,投资于支付股息的企业如Bristol Myers Squibb和Royalty Pharma是有意义的,因为它们的股价可能下跌,但其支付的季度股息是投资者可以保留的 [1] - 这两家公司都在快速提高股息支付,因此投资者的原始投资收益率可能会在退休前翻番几次 [1] Bristol Myers Squibb - 百年制药巨头Bristol Myers Squibb与辉瑞公司合作销售口服抗凝血药物Eliquis,其销售额在第二季度达到年化13.7亿美元 [3] - Bristol Myers Squibb的股息收益率为4.9%,过去5年年增长率为7.9% [3] - Eliquis在欧盟和美国的专利保护将分别于2026年和2028年到期,但Bristol Myers Squibb有其他增长动力来抵消这些损失,如新版Opdivo和首创抗精神病药物KarXT [4][5] Royalty Pharma - Royalty Pharma从众多制药公司获得专利药物的版税,是一种相对可靠的方式来参与制药行业的整体增长趋势 [6] - Royalty Pharma的自由现金流在2020年初以来已增长60%,目前从15种年销售额超10亿美元的药物获得版税 [7][8] - Royalty Pharma自2020年开始支付股息,并已将其增加40%至每股0.21美元,其股息收益率为2.9% [8] - Royalty Pharma预计今年将部署约20亿美元的资本,未来其收到的版税和支付的股息有望呈指数级增长 [8]
